KRAScendo-1: A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Sponsor: Hoffmann-La Roche
Full Title
Protocol BO45217: A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients With Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer
Study Treatment
Divarasib, an oral KRAS G12C inhibitor
Eligibility/Info
Eligible participants will have an unresectable/metastatic non-small cell lug cancer with a KRAS G12C mutation. Participants must have previously been treated in the metastatic setting with platinum-based doublet chemotherapy as well as a PD-(L)1 inhibitor. Participants cannot have been treated with a KRAS G12C or pan-RAS inhibitor prior to enrolling in this clinical trial.
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
Locations
Babylon Medical Oncology
Central Park Medical Oncology
Eastchester Cancer Center
Lake Success Medical Oncology
Patchogue Medical Oncology
Port Jefferson Medical Oncology
Port Jefferson Station Medical Oncology
Riverhead Medical Oncology
Need More Information?
Our team is here to help answer your questions and guide you through your options.